Events

Stay informed on our events

Upcoming Events

15th Annual World Biomarker & CDx Summit | September 22-25, 2025 | Boston, MA

Meet our team at the 15th Annual World Biomarker & CDx Summit | September 22-25, 2025 | Boston, MA. Learn more about the Virtuoso epigenomics platform, by ClearNote Health, which measures active disease biology from drug discovery through development, including dynamic insights into therapy response and resistance - all through a simple blood...

Previous Events

ASCO 2025 – Poster Presentation

Don't miss our poster presentation at ASCO 2025. Colorectal cancer (CRC) is the third most common cancer worldwide and a leading cause of cancer mortality, with ~33% of patients developing metastases and a poor 5-year survival rate of ~15%. While surgical resection...

Digestive Disease Week 2025, May 4–6, San Diego, CA

Join us at DDW25 to explore how ClearNote Health is harnessing the power of the epigenome to drive early pancreatic cancer detection and transform patient outcomes. 📍 Visit us at booth #5525 to learn more about the @Avantect Pancreatic Cancer Test - a simple,...

AACR Annual Meeting 2025, April 25-30, Chicago

We will be attending the AACR Annual Meeting, April 25-30, 2025, taking place at the McCormick Place Convention Center, Chicago, Illinois. Don't miss our poster presentations: Title: 5hmC-sequencing of matched cfDNA and tissue from men with mCRPC is concordant and...

TRI-CON 2025 | March 11-13, San Diego

ClearNote Health will be at TRI-CON 2025. Meet us at booth 3 and learn more about ClearNote Health's Virtuoso Epigenomics Platform. Virtuoso leverages 5hmC epigenomic profiling to uncover active cancer biology patterns from cfDNA in plasma, empowering more efficient...

American Society of Clinical Oncology (ASCO) GU25 | February 13-15

ClearNote Health's VP Translational Research & Head of Biopharma Development, Gulfem D. Guler, is attending the American Society of Clinical Oncology (ASCO) GU25 Symposium, February 13-15, San Francisco. Connect with Gulfem to learn more about ClearNote Health's...

Society for Immunotherapy of Cancer | Nov 6 – 10, 2024

ClearNote presented a poster entitled: “Cell-type specific signatures in plasma cell-free DNA 5-hydroxymethylome enables cancer detection and response monitoring in non-small cell lung cancer patients undergoing anti-PD-1 treatment.”

ISPOR Europe | Nov 17-20, 2024

ClearNote Health presented findings from a clinico-economic analysis of its Avantect Pancreatic Test in a poster entitled “Cell-Free DNA Epigenomic-based Test is Predicted to Be Cost Effective to Manage New-Onset Type 2 Diabetes Patients for Risk of Pancreatic Cancer”...

Epigenomics-based Tests
for Early Cancer Detection

ClearNote Health
Privacy Overview

We use cookies, subject to your consent, to analyze the use of our website and to ensure you get the best experience. Third parties with whom we collaborate can also install cookies in order to show you personalized advertisements on other websites. Read our cookie policy for more information.
Read our privacy policy to understand how ClearNote Health handles personal information that we collect through our digital properties that link to this Privacy Policy, including our website and other activities described in the privacy policy.